: Income Statement Unit : Thousand Baht Performance (Income Statement) Q1.2018 Q1.2017 Increased/ (Decreased) % Income Sales 46,822 43,021 3,801 8.84 Services income 27,672 - 27,672 100.00 Cost of sales

, 2018 with details as follow; unit: million baht Items 6-month period ended 2017 6-month period ended 2018 changes Amount % Amount % Amount % Revenue from sales of goods . . . . . . Cost of sales of goods

Performance (Income Statement) Q3.2018 Q3.2018 Increase/(decrease) % Income Income from Sale of Goods 140,004 151,554 (11,550) (7.62) Income from Sevice 81,443 - 81,443 100.00 Cost of Sale of Goods (108,549

, with 0.18 million baht decrease with no significantly transaction changes. 2. Cost of sale , Profit margin For Quarter 1 of the year 2020, the company had cost of sale of 98.36 million bath compare to

Residence Freehold and Leasehold Property Fund 3 12 (9) (75) 14 28 (14) (50) Total 311 469 (158) (34) 742 925 (183) (20) III Cost of sales breakdown by business segment (Unit: Million Baht) Second quarter 6

or 27.27 percent decreased by following details;  Cost of goods sold as amount of 282.16 Million Baht as 99.25 Million Baht decreased or 26.02 percent when compared to same period of previous year of

Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th 3-Month Period Ending March 31st 2020 2019 Change MB % MB % MB % Cost of Sales 35.76

equipment for lease 80.9 80.6 55.2 0.3 0.4 25.7 46.6 Cost of sales and service 1,348.2 953.9 1,366.0 394.3 41.3 (17.8) (1.3) Cost of equipment for lease 44.2 42.6 31.3 1.6 3.8 12.9 41.2 Administrative

to achieve COD as scheduled in PPA, and construction cost is in line with the budget approved by lenders. This achievement would enable us to keep record of managing the project to commence COD in time

term. In addition to achieving revenue growth, the company-wide cost optimization is ongoing and translated into EBITDA expansion of +9% YoY and +2.4% QoQ to stand at Bt18,905mn, a reported margin of